Commentary: Evidence-Informed Recommendation to Achieve Approximate Parity in the Allowed Number of Doses for Common Psychedelics.
Kelan Thomas, Robert L. Jesse, Nicky J. Mehtani, Jennifer Mitchell, Brian T Anderson
Journal of Psychoactive Drugs 2024 DOI: 10.1080/02791072.2023.2201244 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Topics | 5-MeO-DMT Ayahuasca DMT Ibogaine LSD MDMA Mescaline Psilocybin |
| Keywords | Psychedelic Controlled substances policy Psychoactive policy Decriminalization thresholds Drug quantities Medical doses Treatment amounts |
| Citations | 4 |
| Key points | Proposes that personal possession limits for psychedelic substances should be based on evidence-informed comparable doses rather than arbitrary or inconsistent limits. |
Abstract
In recent years, policymakers have proposed and implemented regulatory changes promoting the deprioritization, decriminalization, or state-level legalization of one or more psychedelic substances, usually referencing data from clinical trials as reasons to support liberalizing drug control policies. As psychedelic policies continue to be drafted, personal possession limits may be considered for inclusion in those regulations. If "allowable amount" limits are to be written into law to set personal possession limits, then such amounts should be more consistently related to psychedelic doses found to be safe and efficacious in clinical trials, existing data on moderate-high doses commonly used in various naturalistic settings, and the few studies that estimate psychedelic dose equivalence based on the intensity of subjective effects. In this commentary, we provide an evidence-informed table of typical moderate-high doses for seven commonly used psychedelic substances. These estimates of comparable moderate-high doses can be used to inform "allowable amount" values for psychedelic substances. When such limits are written into legislation, the adoption of evidence-informed comparable limits akin to those presented here would be an important first step toward ensuring greater parity and consistency in drug policy, relative to limits that have little or no scientific basis.
Citations in the library
Cited by 3
- Innovative Psychedelic Therapies: Harnessing 5-MeO-DMT and DMT for Mental Health Treatment. ACS Medicinal Chemistry Letters November 14, 2024
- Psychedelics and Autism Therapy: A Review of Current Research and Future Directions Current Issues in Molecular Biology April 18, 2026
- Pharmacists and psychedelic medicine JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY October 1, 2023
Cites 22
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology December 1, 2011
- Global Street Food: la cocina de la calle Diseño interior 2009
- Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors Journal of Psychopharmacology October 11, 2017
and 17 more in the library